Human Immunodeficiency Virus Type 1 Reverse Transcriptase Expressing the K70E Mutation Exhibits a Decrease in Specific Activity and Processivity
- 1 August 1998
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 54 (2) , 291-297
- https://doi.org/10.1124/mol.54.2.291
Abstract
Adefovir dipivoxil [9-(2-(bispivaloyloxymethyl)phosphonylmethoxyethyl)adenine (bis-POM PMEA)], an oral prodrug of adefovir (PMEA), is currently in phase III clinical testing for the treatment of human immunodeficiency virus-1 (HIV-1) infection. Previous in vitro experiments have shown that HIV-1 recombinant viruses expressing either a K65R or a K70E mutation in reverse transcriptase (RT) have reduced sensitivity to PMEA and that the K70E mutant also has impaired replication capacityin vitro. Genotypic analyses of samples from patients enrolled in a phase I/II clinical trial of adefovir dipivoxil demonstrated that the K70E RT mutation developed in two of 29 patients during extended therapy. To further investigate the molecular mechanisms involved in the resistance to PMEA, we cloned, expressed, and purified HIV-1 RT enzymes carrying either the K65R or K70E and, for comparison, the M184V mutation. TheKm values of dNTPs for these mutant enzymes were not significantly altered from wild-type RT. TheKi values for the K65R mutant were increased from wild-type by 2–5-fold against a variety of inhibitors, whereas the Ki values for the M184V mutant were increased 12-fold specifically for 2′,3′-dideoxy-3′-thiacytidine (3TC) triphosphate. TheKi values for the K70E mutant were increased for PMEA diphosphate and 3TC triphosphate by 2–3-fold. These results are in agreement with antiviral drug susceptibility assay results. The three recombinant enzymes were also evaluated for their specific activities and processivities. All mutants were reduced in specific activity with respect to wild-type RT. In single-cycle processivity studies, the M184V mutant was, as expected, notably impaired. The K70E mutant was also slightly impaired, whereas the K65R mutant was slightly more processive than wild-type. These results with recombinant K70E RT are consistent with the reduced in vitro replication capacity of the K70E RT mutant of HIV-1 and further demonstrate that the K70E mutation confers minor PMEA and 3TC resistance to HIV-1.Keywords
This publication has 50 references indexed in Scilit:
- High‐Dose Nevirapine in Previously Untreated Human Immunodeficiency Virus Type 1‐Infected Persons Does Not Result in Sustained Suppression of Viral ReplicationThe Journal of Infectious Diseases, 1997
- Comparative Enzymatic Study of HIV-1 Reverse Transcriptase Resistant to 2‘,3‘-Dideoxynucleotide Analogs Using the Single-Nucleotide Incorporation AssayBiochemistry, 1997
- Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of DefectsScience, 1996
- Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: Longitudinal evaluation of six patients under treatmentInfection, 1996
- The K65R Mutation Confers Increased DNA Polymerase Processivity to HIV-1 Reverse TranscriptasePublished by Elsevier ,1996
- Kinetic Properties of Adenine Nucleotide Analogues Against Purified 5-Phosphoribosyl-1-pyrophosphate Synthetases fromE. coli, Rat Liver and Human ErythrocytesNucleosides and Nucleotides, 1995
- Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)The Journal of Infectious Diseases, 1995
- Development of HIV-1 resistance to (−)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complexAIDS, 1995
- Genotypic And Phenotypic Analysis Of Human Immunodeficiency Virus Type 1 Isolates From Patients On Prolonged Stavudine TherapyThe Journal of Infectious Diseases, 1994
- Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapyAIDS, 1989